Form 4: Cardio Diagnostics Director Acquires Future Stock Options

Cardio Diagnostics Holdings Director James Intrater reported the acquisition of 1,559 stock options with an exercise price of $4.01, exercisable from September 30, 2025.

Summary

• Director James Intrater acquired 1,559 stock options in Cardio Diagnostics Holdings, Inc. (CDIO).
• The options have an exercise price of $4.01 per share.
• The transaction date for the acquisition is reported as September 30, 2025.
• These options become exercisable on September 30, 2025, and expire on September 30, 2035.
• Following this transaction, James Intrater beneficially owns a total of 4,953 derivative securities.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director generally indicates confidence in the company's future. The future transaction date suggests a pre-planned compensation event, which is a minor positive signal.

Positives

• An insider (Director James Intrater) is acquiring additional stock options, which can signal confidence in the company's future prospects.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Negatives

• The reported transaction date (September 30, 2025) and signature date (October 3, 2025) are in the future, which is unusual for a Form 4 filing that typically reports past events. This could indicate a planned future grant or a clerical error.

Risks

• The future transaction date (09/30/2025) could be a clerical error, potentially leading to confusion or requiring an amendment.
• The value of the stock options is dependent on the future performance of Cardio Diagnostics Holdings, Inc. common stock.

Future Outlook

The filing indicates a future grant of stock options to a director, suggesting a long-term incentive structure is in place for key management. The options are exercisable from September 30, 2025, and expire in 2035, aligning the director's interests with long-term shareholder value creation.

Industry Context

Form 4 filings are standard for reporting insider transactions. The grant of stock options is a common form of equity compensation used across industries to align management incentives with company performance, particularly in the biotechnology and healthcare sectors.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice in publicly traded companies to incentivize long-term performance.
• An exercise price of $4.01, if it represents the fair market value at the time of grant, is typical for incentive stock options.
• A 10-year expiration period (09/30/2025 to 09/30/2035) is a standard duration for employee and director stock options, providing ample time for value appreciation.

Related Party Transactions

• Grant of 1,559 stock options to Director James Intrater with an exercise price of $4.01.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with long-term shareholder value.

Next Steps

• The options will become exercisable on September 30, 2025.
• The director may choose to exercise these options at any point between the exercisable date and the expiration date (September 30, 2035).

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director, effective in the future. While insider option grants can be a positive signal of confidence, this specific filing does not contain enough material information (e.g., financial results, strategic shifts, large open-market purchases) to warrant a change in investment recommendation from a seasoned investor. It's a standard compensation event.

Keywords

Cardio Diagnostics Holdings, CDIO, Stock Options, Insider Transaction, Form 4, Director, Equity Compensation, Beneficial Ownership